Genome & Company

A314130

KR7314130006

Biotechnology & Medical Research

End-of-day quote Korea S.E. Other stock markets 03:30:00 10/05/2024 am IST			5-day change	1st Jan Change
7,180 ^KRW	0.00%		+4.82%	-42.51%

24/01	Genome & Company Announces Positive Topline Results from Phase 2 Clinical Trial of Combination of GEN-001 and Bavencio®? for the Treatment of Gastric Cancer Poster Presented at ASCO GI	CI
2023	Genome & Company Announces Positive Results from Interim Analysis of Gen-001 Plus Avelumab (Bavencio®?) Phase II Trial	CI

Genome & Company(KOSDAQ:A314130) added to S&P Global BMI Index

September 20, 2021 at 09:30 am IST

Latest news about Genome & Company

Genome & Company Announces Positive Topline Results from Phase 2 Clinical Trial of Combination of GEN-001 and Bavencio®? for the Treatment of Gastric Cancer Poster Presented at ASCO GI	24/01	CI
Genome & Company Announces Positive Results from Interim Analysis of Gen-001 Plus Avelumab (Bavencio®?) Phase II Trial	19/23/19	CI
Genome & Company announced that it has received KRW 23 billion in funding from a group of investors	07/23/07	CI
Genome & Company announced that it expects to receive KRW 23 billion in funding from a group of investors	05/23/05	CI
Genome & Company announced that it has received KRW 34.34975035 billion in funding from a group of investors	02/22/02	CI
Genome & Company announced that it expects to receive KRW 34.34975035 billion in funding from a group of investors	18/22/18	CI
Genome and Company Announces Clinical Trial Collaboration with Merck & Co., Inc	04/22/04	CI
Microbiome CDMO, List Labs, Partners with Genome And Company, to Create Global Microbiome Research, Development, and Manufacturing Powerhouse	21/21/21	CI
Genome & Company(KOSDAQ:A314130) added to S&P Global BMI Index	20/21/20	CI
Genome & Company agreed to acquire a 60% stake in List Biological Laboratories, Inc. for $27 million.	08/21/08	CI
Genome and Company Signs Second Clinical Trial Collaboration and Supply Agreement (Phase 2) with Merck Kgaa, Darmstadt, Germany and Pfizer for Immuno-Oncology Microbiome Study	09/21/09	CI
Genome & Company and Debiopharm Join Forces to Create New Highly Specific Therapies for Cancer Patients	25/21/25	CI
Genome & Company Announces First Patient Dosed in Phase 1/1B Study of GEN-001	27/20/27	CI
Genome & Company announced that it expects to receive KRW 19.99999001 billion in funding from Korea Development Bank, Investment Arm	26/20/26	CI
Scioto Biosciences, Inc. announced that it has received $26.5 million in funding from Genome & Company and other investors	11/20/11	CI
Scioto Biosciences, Inc. announced that it expects to receive $6.50074 million in funding	07/20/07	CI
Genome & Company announced that it has received KRW 4.00002 billion in funding	25/20/25	CI
Genome & Company announced that it expects to receive KRW 4.00002 billion in funding	17/20/17	CI
Genome & Company announced that it has received KRW 3.62991 billion in funding	24/20/24	CI
Genome & Company Receives FDA IND Clearance for GEN-001, its First Anti-Cancer Microbiome Therapeutic	20/20/20	CI
Genome & Company announced that it expects to receive KRW 3.62991 billion in funding	16/20/16	CI
Genome & Co to Raise USD 3 Million in Private Placement	16/20/16	CI
Genome & Company Announces A Clinical Trial Collaboration and Supply Agreement with Merck KGaA and Pfizer Inc	14/20/14	CI
Genome & Company announced that it has received KRW 27.20018096 billion in funding from Tyel Asset Management Co,. Ltd., Smilegate Investment, Inc. and other investors	23/19/23	CI
Genome & Company announced that it has received KRW 2.99999184 billion in funding from Korea Investment & Securities Co., Ltd.	23/19/23	CI

Genome&Company is a company mainly engaged in the research, development, manufacturing and sale of probiotics. Probiotics are mainly used in products including immune oncology therapeutic supplements, dietary supplements, cosmetics and medicines. These products are mainly applied to obesity, diabetes, acne, atopic dermatitis, and cancer complementary therapies.

Sector

Biotechnology & Medical Research

Calendar

13/05/2024 - Q1 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Sector Other Biotechnology & Medical Research

	1st Jan change	Capi.
GENOME & COMPANY	-42.51%	78.75M
MODERNA, INC.	+19.34%	47.02B
LONZA GROUP AG	+48.77%	41.86B
IQVIA HOLDINGS INC.	+0.24%	41.76B
CELLTRION, INC.	-4.27%	28.8B
ICON PUBLIC LIMITED COMPANY	+11.97%	26.05B
ALNYLAM PHARMACEUTICALS, INC.	-21.91%	19.15B
BIO-TECHNE CORPORATION	+4.76%	12.55B
MEDPACE HOLDINGS, INC.	+29.56%	12.34B
CHARLES RIVER LABORATORIES INTERNATIONAL, INC.	-4.53%	11.82B

Other Biotechnology & Medical Research

Genome & Company

Equities

A314130

KR7314130006

Biotechnology & Medical Research

Genome & Company(KOSDAQ:A314130) added to S&P Global BMI Index

Latest news about Genome & Company

Chart Genome & Company

Company Profile

Income Statement Evolution

Sector Other Biotechnology & Medical Research